Narval CC Mandibular Repositioning Device in the Second-line Treatment of Severe Obstructive Sleep Apnea Hypopnea (OSAH)
ORCADES
ORM Narval Mandibular Repositioning Device in the Second-line Treatment of Severe OSAH
2 other identifiers
observational
360
1 country
26
Brief Summary
The purpose of this study is to evaluate the long-term efficacy, tolerance and compliance of ORM Narval Mandibular Repositioning Device (MRD) as a second-line treatment for patients with severe Obstructive Sleep Apnea Hypopnea (OSAH) syndrome who refuse or are intolerant to Continuous Positive Airway Pressure (CPAP) treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2011
Longer than P75 for all trials
26 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 29, 2011
CompletedFirst Posted
Study publicly available on registry
March 30, 2011
CompletedStudy Start
First participant enrolled
May 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
February 27, 2019
CompletedApril 2, 2020
March 1, 2020
7.8 years
March 29, 2011
March 31, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of patients with Apnea/Hypopnea Index (AHI) reduced by at least 50% compared to baseline measured by Polygraphy/Polysomnography (PG/PSG)
5 years
Secondary Outcomes (6)
Percentage of patients with AHI reduced by at least 50% compared to baseline measured by PG/PSG
3 months and 2 years
Percentage of patients who no longer suffer from severe daytime sleepiness (Epworth Sleepiness scale)
3 months, 2 years and 5 years
Sleep quality of life (Quebec Sleep Questionaire)
3 months, 2 years and 5 years
Percentage of patients who stopped the therapy for dento-maxillofacial side effects
6 months, 1, 2, 3, 4 and 5 years
Percentage of patients with satisfactory compliance
3 months, 2 and 5 years.
- +1 more secondary outcomes
Study Arms (1)
ORM Narval MRD
Interventions
Eligibility Criteria
Severe Obstructive Sleep Apnea Hypopnea
You may qualify if:
- Adult patient with severe OSAH (AHI \> 30 or AHI of between 5 and 30 along with severe daytime sleepiness),
- intolerant to or having refused CPAP therapy,
- no dental, parodontal or articulatory contraindications,
- no experience of any mandibular advancement device therapy,
- medical insurance.
You may not qualify if:
- severe psychiatric disorders or severe neuromuscular disorders
- \> 20% of central apneas during the baseline assessment,
- severe OSAH with an AHI \> 30 associated with another sleep pathology (narcolepsy with or without cataplexy, idiopathic hypersomnia, severe restless legs syndrome),
- pregnant or breastfeeding woman,
- Informed consent not signed,
- patient requiring special protection such as patients with appointed guardians and patients without legal or administrative rights,
- patient who is completely or partially edentulous
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ResMedlead
Study Sites (26)
Fondation Bon Sauveur / cabinet médical / cabinet dentaire
Albi, France
CH Antibes / cabinet dentaire
Antibes, France
CH Béziers
Béziers, France
CHU Avicennes
Bobigny, France
Polyclinique du Tondu / cabinet dentaire
Bordeaux, France
CHG Chalon en Champagne
Châlons-en-Champagne, France
CH Compiègne Senlis / cabinets dentaires
Compiègne, France
CHU Grenoble
Grenoble, France
Cabinet médical / cabinet dentaire
Lagny, France
CHRU Lille
Lille, France
Cabinet médical Lyon
Lyon, France
CHU La Timone / cabinet médical
Marseille, France
CHRU Montpellier / Clinique Beau Soleil / Faculté d'Odontologie / cabinet dentaire
Montpellier, France
CH Montreuil
Montreuil, France
Centre Médical Plateau de Haye / cabinet médical / cabinet dentaire
Nancy, France
Maison de la Mutualité / polyclinique de l'Atlantique
Nantes, France
Cabinet médical / cabinet dentaire
Nice, France
Hôpital Bichat Claude Bernard
Paris, France
Hôpital Pitié Salpetriere
Paris, France
Hôtel Dieu
Paris, France
CHU Poitiers
Poitiers, France
CHRU Rennes / polyclinique St Laurent / cabinet dentaire
Rennes, France
CHRU Rouen
Rouen, France
CHU Toulouse
Toulouse, France
Clinique de l'Union
Toulouse, France
CH Valence
Valence, France
Related Publications (3)
Vecchierini MF, Attali V, Collet JM, d'Ortho MP, El Chater P, Kerbrat JB, Leger D, Monaca C, Monteyrol PJ, Morin L, Mullens E, Pigearias B, Meurice JC; ORCADES investigators. A custom-made mandibular repositioning device for obstructive sleep apnoea-hypopnoea syndrome: the ORCADES study. Sleep Med. 2016 Mar;19:131-40. doi: 10.1016/j.sleep.2015.05.020. Epub 2015 Jun 29.
PMID: 26364869RESULTAttali V, Vecchierini MF, Collet JM, d'Ortho MP, Goutorbe F, Kerbrat JB, Leger D, Lavergne F, Monaca C, Monteyrol PJ, Morin L, Mullens E, Pigearias B, Martin F, Tordjman F, Khemliche H, Lerousseau L, Meurice JC; ORCADES investigators. Efficacy and tolerability of a custom-made Narval mandibular repositioning device for the treatment of obstructive sleep apnea: ORCADES study 2-year follow-up data. Sleep Med. 2019 Nov;63:64-74. doi: 10.1016/j.sleep.2019.04.021. Epub 2019 Jun 12.
PMID: 31606651RESULTVecchierini MF, Attali V, Collet JM, d'Ortho MP, Goutorbe F, Kerbrat JB, Leger D, Lavergne F, Monaca C, Monteyrol PJ, Morin L, Mullens E, Pigearias B, Martin F, Khemliche H, Lerousseau L, Meurice JC; ORCADES investigators; Abedipour D, Allard-Redon A, Aranda A, Attali V, Bavozet F, Becu M, Beruben W, Bessard J, Bonafe I, Boukhana M, Chabrol B, Chatte G, Lebret C, Collet JM, Coste O, Dumont N, Durand-Amat S, D'ortho MP, Elbaum JM, De Santerre OG, Goutorbes F, Grandjean T, Guyot W, Hammer D, Havasi C, Huet P, Kerbrat JB, Khemliche H, Koltes C, Leger D, Lacassagne L, Laur X, Lerousseau L, Liard O, Loisel C, Longuet M, Mallart A, Martin F, Merle Beral F, Meurice JC, Mokhtari Z, Monaca C, Monteyrol PJ, Muir JF, Mullens E, Muller D, Paoli C, Petit FX, Pigearias B, Pradines M, Prigent A, Putterman G, Rey M, Samama M, Tamisier R, Tiberge M, Tison C, Tordjman F, Triolet B, Vacher C, Vecchierini MF, Verain A. Sex differences in mandibular repositioning device therapy effectiveness in patients with obstructive sleep apnea syndrome. Sleep Breath. 2019 Sep;23(3):837-848. doi: 10.1007/s11325-018-1766-8. Epub 2018 Dec 22.
PMID: 30580418DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marie-Françoise VECCHIERINI-BLINEAU, Dr
Hôtel Dieu, Paris
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 29, 2011
First Posted
March 30, 2011
Study Start
May 1, 2011
Primary Completion
February 1, 2019
Study Completion
February 27, 2019
Last Updated
April 2, 2020
Record last verified: 2020-03